Results 211 to 220 of about 210,635 (269)

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Fertility and Sterility, 2005
Objective: To compare the efficacy of flare-up and GnRH-antagonist treatment in poor-responder patients. Design: Randomized prospective study. Setting: Assisted reproduction center.
Antonio La Marca, Daniela Tagliasacchi, Annibale Volpe   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor.

Human Reproduction, 2000
Recent suggestions that gonadotrophin-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the studies cited in support of this suggestion are in-vitro studies, testing supra-pharmacological doses of GnRH analogues in cancer cell lines, whereas GnRH antagonists, e.g.
Bernadette Mannaerts, Keith Gordon
exaly   +2 more sources

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists.

Human Reproduction, 2000
When gonadotrophin-releasing hormone (GnRH) was discovered, the agonist and antagonist of GnRH were developed to control the release of FSH and LH by the gonadotrophs. More than 10 years of research were needed to develop a GnRH antagonist free of histamine release.
E R Hernández
exaly   +2 more sources

Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.

Human Reproduction, 2001
The gonadotrophin-releasing hormone (GnRH) antagonists, cetrorelix and ganirelix, have both been approved for ovarian stimulation to prevent a premature LH surge. Since GnRH receptors and their gene expression have been detected in human ovary, concern has risen over whether GnRH antagonists might affect ovarian function.
J M Weiss
exaly   +2 more sources

Applications for GnRH antagonists

Trends in Endocrinology and Metabolism, 2001
Abstract Meeting on the Potential Clinical Applications for Gonadotropin-Releasing Hormone Antagonists was held at the National Institutes of Health in Bethesda, MD, USA on 31 January 2001.
openaire   +2 more sources

GnRH Secretion into CSF in Rams Treated With a GnRH Antagonist

Journal of Neuroendocrinology, 1997
The equilibrium of the brain‐pituitary‐testicular axis is controlled by negative feedback exerted primarily through changes in the circulating concentrations of gonadal steroids. This is usually studied in gonadectomised animals treated with single large doses or constant low levels of exogenous steroid.
Blache, D., Chagas, L.M., Caraty, Alain, Deghenghi, R., Delaleu, Bernadette, Blackberry, M.A., Martin, G.B.   +6 more
openaire   +3 more sources

GnRH-antagonists in reproductive medicine

Archives of Gynecology and Obstetrics, 2005
Suppression of sex steroid production based on desensitisation and down-regulation of pituitary gonadotropin-releasing hormone (GnRH)-receptors by agonistic GnRH-analogues resulting in the blockage of gonadotropin release from the anterior pituitary gland is a well-established approach in a variety of clinical conditions. Antagonistic analogues of GnRH
Georg, Griesinger, Ricardo, Felberbaum, Klaus, Diedrich   +2 more
openaire   +2 more sources

Clinical application of GnRH-antagonists

Molecular and Cellular Endocrinology, 2000
Due to the different pharmacological mode of action, GnRH-antagonists seem to open up new avenues to hormonal treatment in several indications. Although it may be still too early to speculate about the possible end of the era of GnRH-agonists, from what is known today, the advantages of GnRH-antagonists are most evident in our opinion.
R E, Felberbaum, M, Ludwig, K, Diedrich
openaire   +2 more sources

GnRH agonists vs antagonists

Best Practice & Research Clinical Obstetrics & Gynaecology, 2007
Gonadotropin-releasing hormone (GnRH) agonists were introduced in ovarian stimulation for in-vitro fertilization to suppress the premature surge of luteinizing hormone (LH). Although agonist use is accompanied by a series of disadvantages, including hypoestrogenaemia, cyst formation, a requirement for a prolonged period of downregulation, and an ...
B C, Tarlatzis, E M, Kolibianakis
openaire   +2 more sources

Safety of GnRH agonists and antagonists

Expert Opinion on Drug Safety, 2004
The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women and their offspring.
Basil C, Tarlatzis, Helen, Bili
openaire   +2 more sources